In the first step, recurrent genetic abnormalities, NPM1 mutations, and in-frame bZIP domain mutations of CEBPA should be investigated, and if none are present the second step requires assessment for TP53 mutations (VAF  >  10%) and myelodysplasia-related gene mutations or cytogenetic abnormalities. This evidence concerns the gene NPM1 and Myelodysplasia.